@article{1d4e783ffa714ea0a3901f8011ba787e,
title = "Scrambler therapy for treatment-resistant central neuropathic pain in a patient with transverse myelitis",
abstract = "Central neuropathic pain is a severely disabling consequence of conditions that cause tissue damage in the central nervous system. It is often refractory to treatments commonly used for peripheral neuropathy. Scrambler therapy is an emerging noninvasive pain-modifying technique that uses transcutaneous electrical stimulation of nociceptive fibers with the intent of reorganizing maladaptive signaling pathways. It has been examined for the treatment of peripheral neuropathy with favorable safety and efficacy outcomes, but its application to central neuropathic pain has not been reported in transverse myelitis. We describe the use of Scrambler therapy in a patient with persistent central neuropathic pain due to transverse myelitis. The patient had tried multiple drugs for treatment of the pain, but they were not effective or caused adverse effects. After a course of Scrambler therapy, pain scores improved considerably more than what was reported with previous pharmacologic and nonpharmacologic interventions. This case supports further investigation of Scrambler therapy in multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated disorders that damage the central nervous system.",
author = "Mealy, {Maureen A.} and Newsome, {Scott D.} and Kozachik, {Sharon L.} and Michael Levy and Smith, {Thomas J.}",
note = "Funding Information: Financial Disclosures: Ms. Mealy receives training funded in part by grant TL1 TR001078 from the National Center for Advanc- Funding Information: ing Translational Sciences, a component of the National Institutes 2. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical of Health (NIH), and by NIH Roadmap for Medical Research. Dr. implications. BMJ. 2014;348:f7656. The editorial staff of the International Journal of MS Care acknowledges and thanks all of our peer reviewers Newsome receives research support from Biogen, Genentech, the 3. Dworkin RH, O{\textquoteright}Connor AB, Backonja M, et al. Pharmacologic man-from the previous 12 months. The following individuals evaagelumaentte dof mneaurnopuastchrici pptasi nf:r oevmid eNncoev-beamsedb ererc 1om, m2e0n1da7ti,ons. Pain. Department of Defense, the National MS Society, and the Patient-2007;132:237-251. through October 31, 2018 (we apologize if we have missed anyone). We appreciate our reviewers{\textquoteright} support and 4. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. professional expertise. It is through their dedication that we are able to achieve our mission of providing a EMD Serono, Syntimmune, and Gerson Lehrman Group. Dr. Kozahigh-quality peer-reviewed publication.-Arch Neurol. 2012;69:1482-1487. chik receives research support from the NIH Pain Consortium and the 5. Pellkofer HL, Havla J, Hauer D, et al. The major brain endocannabi- Funding Information: Maryland Higher Education Commission. Dr. Levy currently receivesHesham Abboud Nananda F. Col Michael T. Halpernnoid 2-AG controls neuropathic pain and mechanical hyperalgesia inJames J. Marriott Claudio Solaro patients with neuromyelitis optica. PLoS One. 2013;8:e71500. research support from the NIH, Maryland Technology DevelopmentLilyana Amezcua Jonathan E. Cook Laura Hancock Virgil Mathiowetz Matthew Sorenson 6. Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ. A trial of Scram-Corporation, Sanofi, Genzyme, Alexion, Alnylam, Shire, Acorda,Rebekah H. Anguiano Joanna Cooper Kathleen M. Healeybler theraLori Mayerpy in the treatment of cancerJ apcaoibn Js.y Sndorsonmofefs and chronic Publisher Copyright: {\textcopyright} 2019 Consortium of Multiple Sclerosis Centers.",
year = "2019",
month = mar,
day = "1",
doi = "10.7224/1537-2073.2017-083",
language = "English (US)",
volume = "21",
pages = "76--80",
journal = "International Journal of MS Care",
issn = "1537-2073",
publisher = "Consortium of Multiple Sclerosis Centers (CMSC)",
number = "2",
}